...
search icon
avir-img

Atea Pharmaceuticals Inc Share Price

AVIR
NSQ
$4.07
+$0.07
(1.75%)
1D
Industry: Pharmaceuticals Sector: Health Care

Atea Pharmaceuticals Inc Analyst Forecast

Atea Pharmaceuticals Inc Share Price Chart

Atea Pharmaceuticals Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$312.51M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
593.29K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.08
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.46 L
$4.34 H
$4.07

About Atea Pharmaceuticals Inc, Common Stock

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. more

Industry: PharmaceuticalsSector: Health Care

Atea Pharmaceuticals Inc Stock Returns

Time FrameAVIRSectorS&P500
1-Week Return16.28%1.74%2.24%
1-Month Return11.11%1.47%0.71%
3-Month Return23.08%8.01%1.13%
6-Month Return5.54%16.86%8.82%
1-Year Return26.98%7.15%15.58%
3-Year Return-13.04%19%70.86%
5-Year Return-93.12%38.27%85.07%
10-Year Return-86.82%136.11%269.5%

Atea Pharmaceuticals Inc Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue48.63M351.37M192.18M--[{"date":"2020-12-31","value":13.84,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":54.69,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue38.02M29.00K260.00K70.09M83.37M[{"date":"2020-12-31","value":45.61,"profit":true},{"date":"2021-12-31","value":0.03,"profit":true},{"date":"2022-12-31","value":0.31,"profit":true},{"date":"2023-12-31","value":84.07,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit10.61M351.37M(260.00K)(70.09M)(83.37M)[{"date":"2020-12-31","value":3.02,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-0.07,"profit":false},{"date":"2023-12-31","value":-19.95,"profit":false},{"date":"2024-12-31","value":-23.73,"profit":false}]
Gross Margin21.82%100.00%(0.14%)(Infinity%)(Infinity%)[{"date":"2020-12-31","value":21.82,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-0.14,"profit":false},{"date":"2023-12-31","value":null,"profit":false},{"date":"2024-12-31","value":null,"profit":false}]
Operating Expenses21.64M212.99M130.65M94.07M109.58M[{"date":"2020-12-31","value":10.16,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":61.34,"profit":true},{"date":"2023-12-31","value":44.17,"profit":true},{"date":"2024-12-31","value":51.45,"profit":true}]
Operating Income(11.03M)138.38M(130.65M)(164.16M)(192.95M)[{"date":"2020-12-31","value":-7.97,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-94.42,"profit":false},{"date":"2023-12-31","value":-118.63,"profit":false},{"date":"2024-12-31","value":-139.44,"profit":false}]
Total Non-Operating Income/Expense166.00K426.00K22.30M58.45M50.98M[{"date":"2020-12-31","value":0.28,"profit":true},{"date":"2021-12-31","value":0.73,"profit":true},{"date":"2022-12-31","value":38.16,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":87.22,"profit":true}]
Pre-Tax Income(10.95M)138.59M(119.50M)(134.94M)(167.46M)[{"date":"2020-12-31","value":-7.9,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-86.22,"profit":false},{"date":"2023-12-31","value":-97.36,"profit":false},{"date":"2024-12-31","value":-120.83,"profit":false}]
Income Taxes(83.00K)17.40M(3.59M)1.02M925.00K[{"date":"2020-12-31","value":-0.48,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-20.63,"profit":false},{"date":"2023-12-31","value":5.85,"profit":true},{"date":"2024-12-31","value":5.32,"profit":true}]
Income After Taxes(10.86M)121.19M(115.91M)(135.96M)(168.38M)[{"date":"2020-12-31","value":-8.96,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-95.64,"profit":false},{"date":"2023-12-31","value":-112.18,"profit":false},{"date":"2024-12-31","value":-138.94,"profit":false}]
Income From Continuous Operations(10.95M)121.19M(115.91M)(135.96M)(168.38M)[{"date":"2020-12-31","value":-9.03,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-95.64,"profit":false},{"date":"2023-12-31","value":-112.18,"profit":false},{"date":"2024-12-31","value":-138.94,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(10.95M)121.19M(115.91M)(135.96M)(168.38M)[{"date":"2020-12-31","value":-9.03,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-95.64,"profit":false},{"date":"2023-12-31","value":-112.18,"profit":false},{"date":"2024-12-31","value":-138.94,"profit":false}]
EPS (Diluted)(0.97)1.36(1.40)(1.64)(2.00)[{"date":"2020-12-31","value":-71.32,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-102.94,"profit":false},{"date":"2023-12-31","value":-120.59,"profit":false},{"date":"2024-12-31","value":-147.06,"profit":false}]

Atea Pharmaceuticals Inc Ratios

Atea Pharmaceuticals Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

AVIR
Cash Ratio 16.32
Current Ratio 16.66

Atea Pharmaceuticals Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

AVIR
ROA (LTM) -23.86%
ROE (LTM) -37.98%

Atea Pharmaceuticals Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

AVIR
Debt Ratio Lower is generally better. Negative is bad. 0.08
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.92

Atea Pharmaceuticals Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

AVIR
Trailing PE NM
Forward PE NM
P/S (TTM) 1.90
P/B 1.02
Price/FCF NM
EV/R 58.97
EV/Ebitda NM

FAQs

What is Atea Pharmaceuticals Inc share price today?

Atea Pharmaceuticals Inc (AVIR) share price today is $4.07

Can Indians buy Atea Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Atea Pharmaceuticals Inc (AVIR) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in AVIR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Atea Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Atea Pharmaceuticals Inc (AVIR) via the Vested app. You can start investing in Atea Pharmaceuticals Inc (AVIR) with a minimum investment of $1.

How to invest in Atea Pharmaceuticals Inc shares from India?

You can invest in shares of Atea Pharmaceuticals Inc (AVIR) via Vested in three simple steps:

  • Click on Sign Up or Invest in AVIR stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Atea Pharmaceuticals Inc shares
What is Atea Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Atea Pharmaceuticals Inc (AVIR) is $4.34. The 52-week low price of Atea Pharmaceuticals Inc (AVIR) is $2.46.

What is Atea Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Atea Pharmaceuticals Inc (AVIR) is

What is Atea Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Atea Pharmaceuticals Inc (AVIR) is 1.02

What is Atea Pharmaceuticals Inc dividend yield?

The dividend yield of Atea Pharmaceuticals Inc (AVIR) is 0.00%

What is the Market Cap of Atea Pharmaceuticals Inc?

The market capitalization of Atea Pharmaceuticals Inc (AVIR) is $312.51M

What is Atea Pharmaceuticals Inc's stock symbol?

The stock symbol (or ticker) of Atea Pharmaceuticals Inc is AVIR

How Can Investors Use Atea Pharmaceuticals Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Atea Pharmaceuticals Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Atea Pharmaceuticals Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Atea Pharmaceuticals Inc shares for Indian investors?

When investing in Atea Pharmaceuticals Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Atea Pharmaceuticals Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Atea Pharmaceuticals Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Atea Pharmaceuticals Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Atea Pharmaceuticals Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top